Business
Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024
SALT LAKE CITY, May 8, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company, today announced that data from the Phase 2 study of
About this update from Lipocine Inc.
[{"type":"text","content":"SALT LAKE CITY, May 8, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company, today announced that data from the Phase 2 study of LPCN 1148 has been selected for a late breaking oral presentation at the European Association for the Study of Liver (\"EASL\") Congress, to take place June 5 to 8, 2024 in Milan, Italy.\n\n \n \n \n \n \n \n\n \nPresentation Details \nTitle \nIntervention with oral LPCN 1148 improves sarcopenia and hepatic encephalopathy (\"HE\") in patients with cirrhosis: a 52-week phase 2 randomized clinical trial\nPresenter: \nDr. Arun J. Sanyal, MD, Director, Stravitz-Sanyal Institute for Liver Disease and Metabolic Health, Virginia Commonwealth University\nSession Title: \nLate Breaker\nSession Date and Time: \nSaturday, 8 June, 14:00 - 15:30 CEST\nPresentation Time: \n15.15 CEST\nLocation\nGold Room\nAbstract Number:\nLP139\nAbout LPCN 1148 \nLipocine is currently evaluating LPCN 1148 comprising testosterone laurate (\"TL\") for the management of decompensated cirrhosis. The Company believes LPCN 1148 targets unmet needs for patients with cirrhosis including improvements in sarcopenia and quality of life, prevention or reduction in the occurrence of decompensation events such as HE, and improvement in post liver transplant outcomes, survival, and costs.\nAbout Lipocine\nLipocine is a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery to develop differentiated products for CNS disorders. Lipocine has drug candidates in development as well as drug candidates for which we are exploring partnerships. Our drug candidates represent enablement of differentiated, patient friendly oral delivery options for favorable benefit to risk profile which target large addressable markets with significant unmet medical needs. \nLipocine's clinical development candidates include: LPCN 1154, oral brexanolone, for the potential treatment of postpartum depression, LPCN 2101 for the potential treatment of epilepsy, LPCN 2203 an oral candidate targeted for the management of essential tremor, LPCN 2401 an oral proprietary combination of anabolic androgen receptor agonist and α-tocopherol, an antioxidant, as an adjunct therapy to incretin mimetics as an aid for improved body composition in chronic weight management and LPCN 1148, a nove...